Introduction
For many years evidence has been accumulating that there may be a host reaction to malignant melanoma and that this reaction could be immunological. Firstly, melanoma is one of the malignant diseases which occasionally undergoes spontaneous regression (Sumner, 1953; Sumner and Foraker, 1960; Smithrs, 1962 Smithrs, , 1967 Baker, 1964; Everson, 1964; Smith and Steblin, 1965) . Secondly, the disease may remain localized for a long time before it becomes disseminated (Lewis and Kiryabwire, 1968 ; Lewis and Johnson, 1968) . Thirdly, even in patients with disseminated disease some metastatic deposits can regress at the same time as new ones appear and others continue to grow (Bodenham, 1968) . Fourthly, Lewis (1967) has shown in a series of Uganda patients that those with localized tumours often had cytotoxic serum antibody active only against the patient's own melanoma cells. This suggested that there may be tumour-specific antigens in melanoma of a similar type to those found in chemically induced tumours in animals. Morton et al. (1968) , Oettgen et al. (1968) , and Muna et al. (1969) , using immunofluorescence, demonstrated crossreactivity between melanoma cell preparations and the sera from a number of different melanoma patients, but there was nothing to suggest that the antibodies studied were cytotoxic or tumourspecific. P. Mansell in collaboration with one of us (D. C. B.) (to be published) has also detected autoantibodies in some patients with malignant melanoma by several different techniques.
In experimental animals tumour-specific antigens have often been detected, and they may be of two kinds-namely, those situated on the cell surface membrane and those within the cell; frequently the sera of tumour-bearing animals contain antibodies that react with both (cf. Alexander and Fairley, 1967) . Only cell surface membrane antigen would be likely to elicit a reaction whikh influences tumour growth, since both cell-mediated and humoral immunity can kill cells only by reaction with accessible antigens.
In the present study we have tested the reaction between serum and tumour cells from the same and different patients in two different ways: (a) by the ability of sera to inhibit, in the presence of complement, growth or metabolism of melanoma cells in vitro, and (b) by immunofluorescence to assess serum binding to cytoplasmic components of dead cells and to surface membrane of living cells. Two kinds of autoantibody have been recognized in over a third of melanoma patients-one reactive with cell surface which is also cytotoxic, the other reactive with cytoplasmic components. The occurrence of such autoantibodies was closely correlated with non-dissemination of the tumour.
Methods

Tumours and Sera
Immediately after removal the tumour was placed in a sterile container with serum-free tissue culture medium 199 (T.C. 199) and transported at ambient temperature to the laboratory. (Pulvertaft, 1959; Lewis, 1967 
Complement-dependent Cytotoxicity Test
The method, modified from Pulvertaft (1965) , has been reported previously (Lewis, 1967 
Immunofluorescence and Serum Absorptions
Immunofluorescent staining of melanoma cells by patients' sera was carried out by the sandwich method using general procedures described in detail elsewhere (Nairn, 1969 of globulin per ml.). Constant intensity of specific staining by the conjugate in each experiment was confirmed by including a control film treated with serum containing antinuclear factor. Sera from normal human subjects and from patients with diseases other than melanoma were also examined as negative controls. After preliminary experiments at various dilutions, all unabsorbed sera were diluted with an equal volume of the buffered saline before testing.
Tumour-specificity of any positively reacting sera from melanoma patients was assessed by staining experiments in which the activity of unabsorbed sera was compared with that of the sera absorbed twice with fresh homogenate of tumour or of skin from the immediate neighbourhood of the tumour. These homogenates were prepared from 6 ,u frozen sections cut on a cryostat from blocks of tissue roughly 5 mm. square. Additional control of specificity of immunofluorescent reactions was provided by testing films of bronchial carcinoma cells or of lymphoblasts from a leukaemia patient.
Results
At least one of the tests for autoantibodies was carried out on 71 of the 103 tumouTr specimens available for study. Data were not obtained from 32 specimens for various technical reasons. (Table II) . Table III Cytotoxicity Test Of the 68 tumours examined in this way, 24 gave a positive reaction which was directed exclusively against the patient's own tumour cells. There was no reactivity against cells from other patients with malignant melanoma. Table IV illustrates an experiment in which seven sera were tested against 13 tumours, and cytotoxicity was seen only when the serum and tumour cells came from the same patient. Moreover, in a few cytotoxicity tests with absorbed sera neutralization of activity was observed only after absorption with autologous tumour, not with autologous skin, nor with melanomas from other patients.
R.N.A. Synthesis Inhibition
Of the 32 tumours examined in this way 10 gave a positive reaction with the patient's own melanoma cells. When sera were tested against melanoma cells from other patients a lesser degree of inhibition was sometimes observed, presumably the result of activity against " cell-free " cytoplasmic organelles from already damaged cells. Such cross-reactions with internal cytoplasmic components are described in the next section.
Cytoplasmic Immunofluorescence
The characteristic staining pattern (Special Plate, Fig. 2 ) was homogeneous and confined to the cytoplasm, and most of the melanoma cells present in any particular film gave a positive reaction. Only sera from melanoma patients reacted in this way. The identity of the stained cells was established by their morphology and often by their containing melanin pigment. Non-melanoma cells did not stain, except for granulocytes and macrophages, which took up the conjugate non-specifically; these were readily identified microscopically and looked the same in control and test preparations. Table V shows that 11 out of 12 sera giving immunofluorescent staining of autologous melanoma cells also stained cells from representative tumours ME30, with which the autologous serum reacted negatively, and ME36, with which the autologous serum reaction was positive. Eight of these sera reacted with both tumours. About one-third of the sera giving autologous-negative reactions showed reactivity with cells of the two other tumours. We conclude that nearly all melanoma cells, whether from seropositive or seronegative patients, contain a common internal cytoplasmic antigen or antigens. Such antigens were not detected in human lymphoid cells or bronchial carcinoma cells (Table VI) . Cross-reactivity of melanoma patient sera was unrelated to blood groups.
The serum of one seropositive patient, ME4, cross-reacted strongly with all other melanoma cells and to a lesser degree with the lymphoid and bronchial carcinoma cells. It was found to have cytoplasmic autoantibodies of low titre (1: 5) to a variety of mammalian tissues, including human thyroid, rat liver, and rat gastric parietal cells. Absorption studies failed to differentiate these antibodies from any reacting against melanoma cell cytoplasm. Another autologous-positive serum, one of a series from patient ME5, was shown to have antinuclear factor of the solid staining pattern at a titre of 1: 5 in addition to antibody against melanoma cell cytoplasm.
Cells from representative tumours, ME30, ME36, and ME54, were tested against sera from 31 Caucasians without melanoma comprising 12 normal individuals, 7 cases of leukaemia, 4 of glandular fever, 6 of vitiligo, and 2 of bullous pemphigoid. None gave positive cytoplasmic immunofluorescence, though the pemphigoid sera gave the typical basement membrane staining with normal skin sections (Beutner et al., 1967) . The sera ByIJR MEDICAL Jouu~s.Lu from 26 Africans from Uganda and Kenya were also tested: they comprised 12 normal individuals, 9 cases of Burkitt's lymphoma, and 5 of carcinoma of the postnasal space. All but two of these gave immunofluorescent staining of melanoma cells, but of different pattern from that observed with the positive melanoma patient sera. It included diffuse cytoplasmic and weak nuclear staining, and six of the sera, specially examined for autoantibodies to various human and mammalian cells, showed an irregular pattern of low titre activity (1: 5) against a variety of autoantigens. The nature of this serum activity was not investigated except to show that it could be neutralized by absorption with mammalian tissue such as rodent liver homogenate which had no effect on melanoma autoantibodies. The cytoplasmic staining of melanoma cells by sera from melanoma patients was totally inhibited by two serum absorptions with homogenate of the autologous melanoma. In a series in which four positive sera were absorbed with each of three tumours, homologous melanoma homogenates inhibited cytoplasmic immunofluorescence by a variable amount from substantial reduction to total inhibition. In three experiments in which the serum was twice absorbed by homogenates of the patient's skin, a substantial reduction of cytoplasmic immunofluorescent staining was observed as opposed to complete inhibition when the corresponding tumour was used. In a further experiment a similar partial serum neutralization only was obtained by absorption with pigmented Negro skin and by a cell-free crude preparation of melanin obtained from a heavily pigmented melanoma. Heterologous serum absorption with various hamster melanoma tissues, including homogenates of melanoma, pigmented or non-pigmented skin, and liver, had no effect on the immunofluorescent cytoplasmic staining of human melanoma cells. , Fig. 3) ; the solid cytoplasmic staining of any dead cells in the suspension was ignored in reading this test. Two sera, negative by the other tests, gave negative membrane immunofluorescence with the autologous tumour cells. There appeared to be no cross-reaction by positive sera with cells from four homologous tumours examined (two of the sera were autologous-positive and two negative but they had all cross-reacted by cytoplasmic immunofluorescence). Changes in Serum Activity, Natural and Induced
In three patients in whom the serum was originally positive, later sera failed to inhibit growth of the culture autologous melanoma cells when the disease became widespread (Fig. A) . 
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Whether the negative serum reactivity in these cases was due to variation of tumour antigenicity or impairment of host immunological responsiveness cannot be decided from our data.
A change from seronegative to seropositive status has been observed in only two patients (ME1 and ME69 in Table II (Old et al., 1967 We are embarking on a systematic study to deter-mine the immunoglobulin classes of the autoantibodies to melanoma, and the first results on a few sera show that the cytotoxic activity is largely in the IgM serum fraction.
The cytotoxic antibody would be expected to destroy bloodborne melanoma cells and in this way limit dissemination of the tumour. The observation made here that circulating cytotoxic antibody was virtually present only in patients without disseminated disease could be interpreted in this way. The available facts fit the hypothesis that a host reaction mediated by circulating cytotoxic antibodies could be effective in controlling metastases but is of limited value in restricting the growth of solid tumour.
There are close similarities between the present serological reactions to human melanoma and those against chemically induced primary tumours in rodents. Such tumours were the first in which unambiguous tumour-specific antigen in the cell membrane capable of evoking a cytotoxic host reaction was demonstrated. Characteristic features of the antigens in these experimental tumours are that: (1) membrane antigen is unique to each tumour and does not cross-react (cf. Alexander and Fairley, 1967) ; (2) chemically induced sarcomata in rats contained an internal cell antigen which was tumour-specific but common to all the tumours (Wang, 1968) ; (3) in animals bearing primary tumours cell-mediated immunological host reaction against them could be detected only after they had been excised (Mikulska et al., 1966) ; (4) a large tumour mass selectively paralyses the local lymph nodes to the tumourspecific antigens, but an immune reaction can still be induced in the animal by introducing irradiated autologous tumour into the draining areas of non-involved nodes (Alexander et al., 1969) .
To gain a clearer picture of the relationship between host reaction and progress of the disease the capacity of the patient to mount a cell-mediated response against his own tumour must be measured, and experiments on this further problem are in progress with the use of similar techniques.
The correlation between the presence of antibody and the clinical status of the patient raises the question whether some melanomas do not have the membrane antigen and that this favours dissemination. The tests used so far do not allow us to distinguish this possibility from loss of antibody due to some form of immune paralysis coupled perhaps with exhaustion of antibody by the tumour mass. We should eventually be able to decide the question by retesting tumours in the late stage of the disease with sera that had been obtained in the early stages, and late sera against stored or cultured cells.
Routine laboratory testing for autoantibodies in melanoma patients seems desirable, and immunofluorescence with dried melanoma cell films is probably suitable for this purpose, though not necessarily for detecting cytotoxic antibody. It might provide a useful simple method for determining whether an immunotherapeutic procedure has been effective. Sera from patients undergoing immunotherapy could also be tested for cytotoxicity against a standard preparation of tumour cells obtained before therapy and kept deep-frozen or in continued culture.
We are particularly interested in the possibility that autoimmunization with irradiated tumour cells may lead to the appearance of cytotoxic autoantibodies. This procedure has been shown to be useful in experimental animals in retarding the growth of primary sarcoma when the amount of tumour present was very small (Haddow and Alexander, 1964 
